Date: 2011-05-06
Type of information: Granting of a Market Authorisation in the US
Product name: Afinitor®
Compound: everolimus
Therapeutic area: Cancer - Oncology
Action mechanism: mTOR inhibitor. Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. Everolimus binds to the intracellular protein FKBP-12, forming a complex that inhibits mTOR complex-1 (mTORC1) activity. Inhibition of the mTORC1 signalling pathway interferes with the translation and synthesis of proteins by reducing the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongat
Company: Novartis (Switzerland)
Disease: advanced neuroendocrine tumors (NET) of pancreatic origin
Latest news:
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization: 2011-05-06
UE authorization:
Favourable opinion UE:
Favourable opinion USA: 2011-04-12
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news: